Phospho-FOXL2 (S263) Antibody

What is Phospho-FOXL2 (Ser263) Antibody and what does it specifically detect?

Phospho-FOXL2 (Ser263) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of FOXL2 protein only when phosphorylated at serine 263. This antibody is generated using a synthesized peptide derived from human FOXL2 around the phosphorylation site of Ser263, specifically within amino acid range 229-278 . The antibody undergoes affinity purification from rabbit antiserum using epitope-specific immunogen to ensure specificity .

This specificity is crucial because FOXL2 can be phosphorylated at multiple sites, and each phosphorylation event may regulate different aspects of FOXL2 function. The ability to detect specifically the Ser263 phosphorylation allows researchers to investigate this particular post-translational modification and its biological implications.

What are the standard applications for Phospho-FOXL2 (Ser263) Antibody?

Phospho-FOXL2 (Ser263) Antibody has been validated for several experimental applications:

For Western Blot applications, researchers should optimize protein loading (typically 20-40 μg of total protein) and blocking conditions. The antibody's high specificity makes it valuable for comparing phosphorylation levels between different experimental conditions .

What is the biological significance of FOXL2 and its phosphorylation?

FOXL2 (Forkhead box protein L2) is a transcription factor critically involved in:

• Ovary differentiation and maintenance

• Repression of the genetic program for somatic testis determination

• Prevention of trans-differentiation of ovary to testis through transcriptional repression of SOX9

• Regulation of granulosa cell differentiation and follicle maturation

• Modulation of apoptotic activity in ovarian cells

Phosphorylation of FOXL2 at Ser263 appears to be a significant post-translational modification that regulates its transcriptional activity. Research indicates that phosphorylation enhances FOXL2's function as a transcriptional repressor, particularly for genes like StAR (Steroidogenic Acute Regulatory protein), which is a marker of granulosa cell differentiation . This phosphorylation may be a control mechanism regulating the rate of granulosa cell differentiation and follicle maturation, with dysregulation potentially contributing to premature ovarian failure in BPES type I (Blepharophimosis, Ptosis, and Epicanthus inversus Syndrome) .

What experimental controls should be included when using Phospho-FOXL2 (Ser263) Antibody?

When designing experiments with Phospho-FOXL2 (Ser263) Antibody, researchers should include the following controls:

• Phosphatase treatment control: Treating a portion of your sample with alkaline phosphatase (AP) before immunoblotting. This should eliminate the phosphorylated band, confirming that the detected signal is indeed phosphorylated FOXL2 .

• Phosphatase inhibitor control: Including phosphatase inhibitors in your lysis buffer should preserve the phosphorylated form of FOXL2, resulting in detection of both phosphorylated and non-phosphorylated bands .

• Combined treatment control: Samples treated with both alkaline phosphatase and phosphatase inhibitors should show preservation of the phosphorylated band, confirming the specificity of the detection system .

• Non-phospho-specific FOXL2 antibody: Running parallel blots with a total FOXL2 antibody (detecting both phosphorylated and non-phosphorylated forms) allows for normalization and comparison of phosphorylation levels across samples .

• Negative control tissues: Include tissues known not to express FOXL2 (such as muscle) to confirm antibody specificity .

How can researchers validate the specificity of Phospho-FOXL2 (Ser263) Antibody?

To validate antibody specificity, researchers should:

• Perform immunoprecipitation followed by Western blot: Immunoprecipitate with a FLAG-tagged FOXL2 antibody, then probe with both FOXL2 antibody and phosphoserine antibody. The phosphorylated FOXL2 band should be detected by both antibodies .

• Conduct phosphatase treatment validation: Compare immunoblots of samples with and without phosphatase treatment. The phosphorylated band should disappear after phosphatase treatment .

• Use competitive peptide blocking: Pre-incubate the antibody with the immunizing phosphopeptide before immunoblotting. This should eliminate specific signals.

• Compare with genetic models: When possible, compare detection in wild-type samples versus samples with FOXL2 mutations or knockouts.

• Cross-validate with mass spectrometry: For definitive validation, phosphorylation at Ser263 can be confirmed using phospho-proteomic mass spectrometry approaches.

What are the optimal protocols for using Phospho-FOXL2 (Ser263) Antibody in Western Blot analysis?

Optimal Western Blot Protocol:

• Sample preparation:

  • Harvest cells/tissues in RIPA buffer supplemented with phosphatase inhibitors (critical for preserving phosphorylation)

  • For tissue samples, rapidly freeze in liquid nitrogen immediately after collection to preserve phosphorylation states

  • Determine protein concentration using Bradford or BCA assay

• SDS-PAGE separation:

  • Load 20-40 μg of total protein per lane

  • Use 10-12% polyacrylamide gels for optimal separation

  • Include molecular weight markers (FOXL2 has a molecular weight of approximately 39-50 kDa)

• Transfer and blocking:

  • Transfer to PVDF membrane at 100V for 1-2 hours

  • Block with 5% BSA in TBST (not milk, which contains phosphatases)

• Antibody incubation:

  • Dilute Phospho-FOXL2 (Ser263) Antibody 1:500-1:2000 in 5% BSA/TBST

  • Incubate overnight at 4°C

  • Wash 3x with TBST

• Detection:

  • Use HRP-conjugated anti-rabbit secondary antibody

  • Develop using enhanced chemiluminescence

  • Expected result: Phosphorylated FOXL2 should appear as a band at approximately 40-50 kDa

How does phosphorylation at Ser263 affect FOXL2 function compared to other phosphorylation sites?

FOXL2 can be phosphorylated at multiple serine residues, including Ser238 and Ser263. Research suggests different functional outcomes depending on the phosphorylation site:

• Ser263 phosphorylation: Evidence suggests this modification enhances FOXL2's transcriptional repressor activity, particularly for the StAR gene promoter. This may regulate granulosa cell differentiation and follicle maturation rates .

• Ser238 phosphorylation: While less extensively studied than Ser263, antibodies detecting this modification are available , suggesting biological relevance that may differ from Ser263 phosphorylation.

The differential phosphorylation of FOXL2 appears to be part of a complex regulatory network. Research indicates that LATS1 (Large Tumor Suppressor 1) can phosphorylate FOXL2 at serine residues, enhancing its transcriptional repression activity . This kinase-mediated regulation creates another layer of control over FOXL2 function in ovarian development.

Researchers investigating these different phosphorylation events should consider:

• Using site-specific phospho-antibodies to distinguish between different phosphorylation events

• Employing site-directed mutagenesis (e.g., S263A mutations) to prevent phosphorylation at specific sites

• Conducting comparative functional assays to determine how different phosphorylation events affect FOXL2's interaction with DNA and other proteins

What is the relationship between LATS1 kinase and FOXL2 phosphorylation?

LATS1 has been identified as a serine/threonine kinase that interacts with and phosphorylates FOXL2. Key findings about this interaction include:

• Physical interaction: Yeast two-hybrid screening identified LATS1 as a potential FOXL2-interacting protein, which was confirmed by coimmunoprecipitation assays .

• Kinase activity: LATS1 phosphorylates FOXL2 at serine residues. This phosphorylation enhances FOXL2's activity as a transcriptional repressor of the StAR promoter .

• Co-expression patterns: FOXL2 and LATS1 are coexpressed in developing mouse gonads and in granulosa cells of small and medium follicles in the mouse ovary, supporting their functional relationship in vivo .

• Phenotypic correlation: LATS1 deletion in mice results in an ovarian phenotype similar to premature ovarian failure (POF), which is also associated with FOXL2 mutations. This suggests a common regulatory pathway .

For researchers studying this interaction, methodological approaches could include:

• In vitro kinase assays with purified LATS1 and FOXL2

• Co-immunoprecipitation experiments in ovarian cell models

• Transcriptional reporter assays comparing wild-type FOXL2 with phosphomimetic and phospho-deficient mutants

• Analysis of downstream gene expression changes when LATS1-FOXL2 interaction is disrupted

How does estradiol treatment affect FOXL2 phosphorylation and expression?

Estradiol (E2) treatment has been shown to influence FOXL2 expression in a tissue-specific and dose-dependent manner. In research on Dabry's sturgeon:

• Dose-dependent response in ovaries: A linear relationship was observed where increasing E2 concentration directly correlated with increased FOXL2 expression in ovarian tissue .

• Non-linear response in testes: Interestingly, FOXL2 expression in testicular tissue showed a peak at intermediate E2 dosage followed by decreased expression at higher concentrations, suggesting different regulatory mechanisms between gonads .

For researchers studying estradiol's effects on FOXL2 phosphorylation specifically at Ser263, suggested approaches include:

• Treating cell cultures with varying E2 concentrations and analyzing Ser263 phosphorylation using Phospho-FOXL2 (Ser263) Antibody

• Comparing total FOXL2 levels with phosphorylated FOXL2 levels following E2 treatment

• Investigating the temporal dynamics of phosphorylation following E2 treatment

• Examining the effects of estrogen receptor antagonists on FOXL2 phosphorylation

What are the challenges in detecting phosphorylated FOXL2 in tissue samples?

Detecting phosphorylated FOXL2 in tissue samples presents several methodological challenges:

• Rapid dephosphorylation: Phosphorylation states can be extremely labile and may be lost during tissue processing. Tissues must be harvested and snap-frozen in liquid nitrogen immediately to preserve phosphorylation status .

• Phosphatase activity in samples: Endogenous phosphatases can rapidly remove phosphate groups during sample preparation. This necessitates the consistent use of phosphatase inhibitor cocktails in all buffers .

• Low abundance of phosphorylated protein: The phosphorylated form may represent only a fraction of the total FOXL2 pool, making detection challenging. Enrichment techniques may be required.

• Tissue-specific expression patterns: FOXL2 expression varies significantly between tissues, with highest expression in ovaries, particularly granulosa cells . This means careful sample selection is critical.

• Multiple phosphorylation sites: The presence of multiple phosphorylation sites (Ser238, Ser263) means researchers must use site-specific antibodies to distinguish between different phosphorylated forms .

To overcome these challenges, researchers should:

• Process tissues rapidly with appropriate preservation techniques

• Use phosphatase inhibitors consistently

• Consider phospho-enrichment techniques prior to Western blotting

• Include appropriate controls (phosphatase-treated samples)

• Use both total FOXL2 and phospho-specific antibodies in parallel

How can researchers use Phospho-FOXL2 (Ser263) Antibody in studying reproductive disorders?

Phospho-FOXL2 (Ser263) Antibody offers significant potential for investigating reproductive disorders, particularly those involving ovarian dysfunction:

• Premature Ovarian Failure (POF) research: Mutations in FOXL2 can lead to premature ovarian failure, potentially through dysregulation of phosphorylation. Researchers can compare phosphorylation patterns between normal and POF patient samples to identify alterations .

• BPES (Blepharophimosis, Ptosis, and Epicanthus inversus Syndrome) studies: Type I BPES includes POF as a symptom and is associated with FOXL2 mutations. Investigating how these mutations affect phosphorylation at Ser263 may provide insights into the molecular mechanisms of the disease .

• Polycystic Ovary Syndrome (PCOS) investigations: While not directly linked to FOXL2 in the literature provided, researchers could explore whether altered FOXL2 phosphorylation plays a role in the abnormal follicular development and steroidogenesis seen in PCOS.

• Granulosa cell tumor research: FOXL2 mutations are implicated in granulosa cell tumors. The phosphorylation status at Ser263 might differ between normal and tumor tissues, potentially serving as a biomarker or therapeutic target.

Methodological approaches could include:

• Comparative studies of phosphorylated FOXL2 in normal versus pathological ovarian tissues

• Analysis of how disease-associated FOXL2 mutations affect phosphorylation at Ser263

• Investigation of kinase-phosphatase imbalances that might alter FOXL2 phosphorylation in disease states

• Correlation of phosphorylation patterns with clinical outcomes and disease progression

How can Phospho-FOXL2 (Ser263) Antibody be used to investigate transcriptional regulation networks?

FOXL2 is involved in complex transcriptional regulatory networks in ovarian development and function. Phospho-FOXL2 (Ser263) Antibody can help elucidate these networks through:

• Chromatin immunoprecipitation (ChIP) assays: Using the phospho-specific antibody for ChIP can identify genomic regions bound specifically by the phosphorylated form of FOXL2, potentially revealing phosphorylation-dependent target genes.

• Protein complex analysis: Immunoprecipitation with the phospho-specific antibody followed by mass spectrometry can identify proteins that preferentially interact with phosphorylated FOXL2 .

• Transcriptional reporter assays: Comparing the activity of wild-type FOXL2 versus phospho-mimetic or phospho-deficient mutants on reporter constructs can reveal how phosphorylation at Ser263 affects transcriptional activity on specific promoters.

Research has already established that FOXL2 regulates or interacts with several important genes and pathways:

• StAR gene repression: Phosphorylation enhances FOXL2's repression of the StAR gene, influencing steroidogenesis

• SOX9 repression: FOXL2 prevents trans-differentiation of ovary to testis through repression of SOX9

• CYP19 regulation: FOXL2 regulates CYP19 expression, which is involved in estrogen biosynthesis

• SMAD3-dependent transcription: FOXL2 participates in SMAD3-dependent transcription of FST via intronic SMAD-binding elements

• SIRT1 activation: FOXL2 activates SIRT1 transcription under cellular stress conditions

What future research directions could benefit from Phospho-FOXL2 (Ser263) Antibody?

Several promising research directions could leverage Phospho-FOXL2 (Ser263) Antibody:

• Development of phosphorylation-specific therapeutics: Understanding the role of Ser263 phosphorylation could lead to targeted therapies for conditions involving FOXL2 dysfunction.

• Biomarker development: Phosphorylation status at Ser263 could potentially serve as a biomarker for ovarian reserve or follicular health.

• Interaction with environmental factors: How environmental exposures (endocrine disruptors, toxins) affect FOXL2 phosphorylation patterns could reveal mechanisms of reproductive toxicity.

• Species conservation studies: Comparing FOXL2 phosphorylation across species could provide insights into evolutionary aspects of reproductive biology and conservation strategies for endangered species like Dabry's sturgeon .

• Single-cell analysis: Combining phospho-specific antibodies with single-cell techniques could reveal cell-to-cell variability in FOXL2 phosphorylation within follicles at different developmental stages.

• Developmental timing research: Investigating how phosphorylation patterns change during critical periods of gonadal development could clarify the temporal aspects of sex determination and differentiation.

• Integration with other post-translational modifications: FOXL2 undergoes other modifications, including SUMOylation . Research into how these modifications interact with phosphorylation could reveal complex regulatory mechanisms.

These research directions would benefit from continued refinement of phospho-specific detection methods and the development of complementary tools for studying FOXL2 regulation and function.